Task 3.1
Identification of lead nanobodies targeting CD8β, CD69 & CD163...
Description
We will use nanobody technology as a main vehicle platform for new tracer development as these antibody-fragments have already shown excellent specificity and sensitivity for imaging in oncology and inflammation (De Vos J. et al., 2013; Krasniqi A. e...
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- F. HOFFMANN-LA ROCHE AGSwitzerlandhttps://www.roche.com/
- PFIZER LIMITEDUnited Kingdom of Great Britain and Northern Ireland (the)https://www.pfizer.com/
- TAKEDA DEVELOPMENT CENTRE EUROPE LTDUnited Kingdom of Great Britain and Northern Ireland (the)
- University Medical Centre Groningen (UMCG)Netherlands (the)https://www.umcg.nl/
- VRIJE UNIVERSITEIT BRUSSELBelgiumhttps://www.vub.be/en/home
- WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTERGermanyhttps://www.uni-muenster.de/en/
Networks
Part of networks...